ABOUT US

The Clinical Pharmacokinetic Laboratory (CPL) was established in 1977 as a subdivision of the Department of Pharmacology, School of Pharmacy at the North-West University, Potchefstroom Campus.  Today CPL is an entity of the Centre for Pharmaceutical and Biomedical Services, which is in partnership with the North-West University. 

Initially CPL provided independent blood level analysis and pharmacokinetic services for anti-epileptic drugs (AED) to the South African National Epilepsy League (SANEL).  Services have since then been extended, where CPL acts as a national platform that serves national and international clients in private and public (government) sectors.

CPL specialises in the analysis of anti-epileptic drug (AED) levels in blood for therapeutic drug monitoring (TDM) purposes as implemented by practitioners.  A supplemented pharmacokinetic service may also be provided on request.

MISSION

The mission of CPL is to provide specialised TDM services for anti-epileptic drugs, assisting practitioners in making therapeutic adjustments when necessary.  CPL strives to produce accurate and trustworthy results in accordance with the ISO 17025:2005 quality standard.

QUALITY POLICY

CPL subscribes to a quality policy that is guided by the ISO 17025:2005 standard.  Both CPL management and personnel are committed to the quality policy, a high level of quality service to clients and the continuing development and improvement of CPL services.

SERVICES

The following drugs are monitored, and through TDM reporting serum/plasma drug levels are reported in reference to the desired therapeutic range of the drug monitored:

  • Lamotrigine
  • Oxcarbazepine
  • Clonazepam
  • Phenytoin
  • Carbamazepine
  • Levetiracetam

TDM entails the utilisation of serum/plasma drug level data and individualised pharmacokinetic parameters to optimise dosage adjustments for a particular patient.

TDM may assist in the following:

  • Optimisation of achieving the desired therapeutic range, reducing therapeutic costs
  • Reducing hospital costs
  • Reducing adverse effects

TDM may be required in the following instances:

  • Uncontrolled seizures
  • Possible drug toxicity
  • Altered drug kinetics due to pregnancy, other illnesses or drug interactions
  • Dose adjustments